BMO Slashes Lithium Americas Target as Capex Costs Jump
BMO Capital Markets cuts Lithium Americas' price target to $4.50, citing 15% capex inflation at Thacker Pass and ongo...
Investing
Learn smart investing strategies for stocks, ETFs, bonds, and building long-term wealth.
5,594 articles
What Retirement Really Looks Like with $3 Million Savings
A $3 million retirement nest egg offers substantial income options, but taxes, Medicare costs, and withdrawal strateg...
World’s Most Advanced Tanks: Investing in Defense Tech Now
As drone-saturated battlefields rise, the world’s most advanced tanks drive a new era of defense spending. This repor...
Stocks to Watch ASAP Before SpaceX IPO Shifts Markets
As SpaceX moves closer to a historic IPO, investors are eyeing space peers for immediate upside. This report highligh...
AST SpaceMobile Rocket Drop Then Sparks RKLB Bets Today
AST SpaceMobile and Rocket Lab fell roughly 4% intraday, then clawed back losses as markets rotated amid a volatile w...
Price Rallies After Trump Pause on Iran Strikes: XRP Moves
XRP rose roughly 7% after a delay in Iranian strikes ordered by Donald Trump, lifting the token to around $1.46. The ...
Better Buy: Apple vs Meta Signals for 2026 Playbook
Apple posted a record iPhone quarter and Meta pushed ad revenue higher, but each faces starkly different bets on AI a...
Tesla Finally Catches Break in Europe on Higher Sales
Tesla reports its first European sales uptick in over a year, a modest but meaningful turn that investors are watchin...
Xcel Energy Could Year-End Rally as UBS Sees Value
UBS boosts its price target on Xcel Energy to $89 while maintaining a Buy rating, saying the stock could year-end hig...
From $383 $500: Bofa’s Microsoft Call Fuels Azure Momentum
Bank of America reinstates Buy on Microsoft, guiding toward a $500 price target as Azure growth and Copilot adoption ...
What OpenAI’s Risk Disclosure Signals Microsoft’s Position
OpenAI’s IPO-style risk disclosure confirms Microsoft’s central role in its operations, signaling potential leverage ...
Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...